11/29
07:16 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
11/26
02:01 pm
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
06:04 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Low
Report
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
11/25
08:53 am
agio
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst [Yahoo! Finance]
11/24
09:04 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $32.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $32.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/21
02:55 pm
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at JPMorgan Chase & Co. from $37.00 to $20.00. They now have a "neutral" rating on the stock.
Low
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at JPMorgan Chase & Co. from $37.00 to $20.00. They now have a "neutral" rating on the stock.
11/21
05:30 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
11/20
12:26 pm
agio
How Recent Events Are Reshaping the Agios Pharmaceuticals Investment Story [Yahoo! Finance]
Low
Report
How Recent Events Are Reshaping the Agios Pharmaceuticals Investment Story [Yahoo! Finance]
11/20
08:07 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at HC Wainwright from $56.00 to $48.00. They now have a "buy" rating on the stock.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at HC Wainwright from $56.00 to $48.00. They now have a "buy" rating on the stock.
11/20
08:07 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at Bank of America Corporation from $54.00 to $32.00. They now have a "buy" rating on the stock.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at Bank of America Corporation from $54.00 to $32.00. They now have a "buy" rating on the stock.
11/20
08:07 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $40.00 to $25.00. They now have a "neutral" rating on the stock.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $40.00 to $25.00. They now have a "neutral" rating on the stock.
11/20
08:05 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $34.00 price target on the stock, down previously from $40.00.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $34.00 price target on the stock, down previously from $40.00.
11/19
02:46 pm
agio
Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility [Seeking Alpha]
Low
Report
Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility [Seeking Alpha]
11/19
01:16 pm
agio
Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by analysts at Royal Bank Of Canada from an "outperform" rating to a "sector perform" rating. They now have a $28.00 price target on the stock.
Low
Report
Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by analysts at Royal Bank Of Canada from an "outperform" rating to a "sector perform" rating. They now have a $28.00 price target on the stock.
11/19
10:42 am
agio
Agios Pharmaceuticals (AGIO): Assessing Current Valuation After Strong Revenue Growth and Improved Net Income [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals (AGIO): Assessing Current Valuation After Strong Revenue Growth and Improved Net Income [Yahoo! Finance]
11/19
07:00 am
agio
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
High
Report
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
11/14
01:10 pm
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
06:56 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/3
09:01 am
agio
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
Medium
Report
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
10/30
06:30 am
agio
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
10/18
10:00 am
agio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
10/18
07:39 am
agio
Evaluating Agios Pharmaceuticals After 16% Rally and Positive Early Data on Mitapivat in Sickle Cell Disease [Yahoo! Finance]
Low
Report
Evaluating Agios Pharmaceuticals After 16% Rally and Positive Early Data on Mitapivat in Sickle Cell Disease [Yahoo! Finance]
10/17
08:15 am
agio
Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia
Low
Report
Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia
10/17
08:00 am
agio
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
Low
Report
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia